Research programme: autoimmune and inflammatory disease antibody therapeutics - Dyax/Syntonix

Drug Profile

Research programme: autoimmune and inflammatory disease antibody therapeutics - Dyax/Syntonix

Latest Information Update: 23 Feb 2011

Price : $50

At a glance

  • Originator Dyax; Syntonix Pharmaceuticals
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Inflammation

Most Recent Events

  • 23 Feb 2011 No development reported - Preclinical for Autoimmune disorders in USA (Parenteral)
  • 23 Feb 2011 No development reported - Preclinical for Inflammation in USA (Parenteral)
  • 24 Jul 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top